您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Tovetumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tovetumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1243266-04-7
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
MEDI-575
产品介绍
Tovetumab (MEDI-575) 是一种抗PDGFRα单克隆抗体,可选择性的阻断 PDGFRα 信号转导。Tovetumab 可用于胶质母细胞瘤和非小细胞肺癌 (NSCLC) 的研究。
生物活性

Tovetumab (MEDI-575) is an anti-PDGFRαmonoclonal antibody that selectively blocks thePDGFRαsignal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lungcancer(NSCLC)[1][2].

IC50& Target[1]

PDGFRα

 

体外研究
(In Vitro)

Tovetumab (10-100 nM, 1-2 h) binds to PDGFRα on H1703 cells (determined by Alexa647-labeled tovetumab)[1].
Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFRα in MG-63 cells[2].
Tovetumab (0.001-100 nM, 72 h ) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs)[2].

体内研究
(In Vivo)

Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys[1].
Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts[2].

Animal Model:Cynomolgus monkey[1]
Dosage:0.6, 6.0, and 60 mg/kg
Administration:Intravenous injection (i.v.)
Result:Induced >100- fold increases in circulating concentrations of PDGF-AA.
Animal Model:U118 glioma xenografts (CB17 SCID)[2]
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.), twice per week.
Result:Produced 101% inhibition of tumor growth.
Clinical Trial
性状

Liquid

CAS 号

1243266-04-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.